The Relationship of Polymorphisms in ABCC2 and SLCO1B3 with Docetaxel Pharmacokinetics and Neutropenia: CALGB 60805 (Alliance)

Overview

Journal Pharmacogenet Genomics

Specialties Genetics
Pharmacology

Date 2012 Nov 29

PMID 23188068

Citations 11

Authors

Lionel D Lewis

Antonius A Miller

Kouros Owzar

Robert R Bies

Svetlana Markova

Chen Jiang

Deanna L Kroetz

Merrill J Egorin

Howard L McLeod

Mark J Ratain

Affiliations

Soon will be listed here.

Abstract

Docetaxel-related neutropenia was associated with polymorphisms in the drug transporters ABCC2 and SLCO1B3 in Japanese cancer patients. We hypothesized that this association is because of reduced docetaxel clearance, associated with polymorphisms in those genes. We studied 64 US cancer patients who received a single cycle of 75 mg/m of docetaxel monotherapy. We found that the ABCC2 polymorphism at rs-12762549 trended to show a relationship with reduced docetaxel clearance (P=0.048), but not with neutropenia. There was no significant association of the SLCO1B3 polymorphisms with docetaxel clearance or neutropenia. We conclude that the relationship between docetaxel-associated neutropenia and polymorphisms in drug transporters identified in Japanese patients was not confirmed in this cohort of US cancer patients.

Citing Articles

Life-Threatening Docetaxel Toxicity in a Patient With Reduced-Function CYP3A Variants: A Case Report.

Powell N, Shugg T, Ly R, Albany C, Radovich M, Schneider B Front Oncol. 2022; 11:809527.

PMID: 35174070 PMC: 8841796. DOI: 10.3389/fonc.2021.809527.

Pharmacogenetics-Based Preliminary Algorithm to Predict the Incidence of Infection in Patients Receiving Cytotoxic Chemotherapy for Hematological Malignancies: A Discovery Cohort.

Martinez M, Alveal E, Soto T, Bustamante E, Avila F, Bangdiwala S Front Pharmacol. 2021; 12:602676.

PMID: 33776761 PMC: 7988592. DOI: 10.3389/fphar.2021.602676.

Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.

Hertz D Expert Opin Drug Metab Toxicol. 2021; 17(2):227-239.

PMID: 33401943 PMC: 7864890. DOI: 10.1080/17425255.2021.1856367.

Different treatment efficacies and side effects of cytotoxic chemotherapy.

Li L, Chong Q, Wang L, Cher G, Soo R J Thorac Dis. 2020; 12(7):3785-3795.

PMID: 32802458 PMC: 7399437. DOI: 10.21037/jtd.2019.08.63.

Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation.

Varnai R, Koskinen L, Mantyla L, Szabo I, FitzGerald L, Sipeky C Genes (Basel). 2019; 10(8).

PMID: 31398933 PMC: 6723793. DOI: 10.3390/genes10080599.

References

Zamboni W, Combest A, DeLoia J, Edwards R, Bridges A, Zamboni B . Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemother Pharmacol. 2011; 68(5):1255-62. DOI: 10.1007/s00280-011-1609-9. View

Lewis L, Miller A, Rosner G, Dowell J, Valdivieso M, Relling M . A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007; 13(11):3302-11. DOI: 10.1158/1078-0432.CCR-06-2345. View

Huisman M, Chhatta A, van Tellingen O, Beijnen J, Schinkel A . MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005; 116(5):824-9. DOI: 10.1002/ijc.21013. View

Eichelbaum M, Burk O . CYP3A genetics in drug metabolism. Nat Med. 2001; 7(3):285-7. DOI: 10.1038/85417. View

Baker S, Verweij J, Cusatis G, van Schaik R, Marsh S, Orwick S . Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2008; 85(2):155-63. PMC: 4612590. DOI: 10.1038/clpt.2008.95. View

Bruno R, Vivier N, Vergniol J, De Phillips S, Montay G, Sheiner L . A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996; 24(2):153-72. DOI: 10.1007/BF02353487. View

Bosch T, Huitema A, Doodeman V, Jansen R, Witteveen E, Smit W . Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res. 2006; 12(19):5786-93. DOI: 10.1158/1078-0432.CCR-05-2649. View

Schwarz U, Zu Schwabedissen H, Tirona R, Suzuki A, Leake B, Mokrab Y . Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics. 2011; 21(3):103-14. PMC: 3044558. DOI: 10.1097/FPC.0b013e328342f5b1. View

Fulton B, Spencer C . Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs. 1996; 51(6):1075-92. DOI: 10.2165/00003495-199651060-00011. View

10.

Eisenhauer E, Vermorken J . The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998; 55(1):5-30. DOI: 10.2165/00003495-199855010-00002. View

11.

Bardelmeijer H, Ouwehand M, Buckle T, Huisman M, Schellens J, Beijnen J . Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 2002; 62(21):6158-64. View

12.

Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V . Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther. 2006; 79(6):570-80. DOI: 10.1016/j.clpt.2006.02.003. View

13.

Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y . Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008; 99(5):967-72. PMC: 11159748. DOI: 10.1111/j.1349-7006.2008.00765.x. View

14.

Hirouchi M, Suzuki H, Itoda M, Ozawa S, Sawada J, Ieiri I . Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res. 2004; 21(5):742-8. DOI: 10.1023/b:pham.0000026422.06207.33. View

15.

de Graan A, Lancaster C, Obaidat A, Hagenbuch B, Elens L, Friberg L . Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res. 2012; 18(16):4433-40. PMC: 3464009. DOI: 10.1158/1078-0432.CCR-12-0761. View

16.

Baker S, Sparreboom A, Verweij J . Clinical pharmacokinetics of docetaxel : recent developments. Clin Pharmacokinet. 2006; 45(3):235-52. DOI: 10.2165/00003088-200645030-00002. View

17.

Smith N, Acharya M, Desai N, Figg W, Sparreboom A . Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005; 4(8):815-8. DOI: 10.4161/cbt.4.8.1867. View

18.

Chew S, Singh O, Chen X, Ramasamy R, Kulkarni T, Lee E . The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol. 2011; 67(6):1471-8. DOI: 10.1007/s00280-011-1625-9. View